Abstract

Background: At present, the prevalence of pregestational diabetes is 2.2% with an overall prevalence of hyperglycaemia in pregnancy of about 16.2%. Fetuses of diabetic mothers are at risk of functional cardiac abnormalities without structural cardiac anomalies especially in the third trimester. The main aim of this study was to assess the association of diabetes with different fetal echocardiographic parameters.

Methods: A case control study comprising a total of 120 pregnant women (60 cases and 60 controls). The cases group included fetuses of mothers known to have pre-gestational type 2 diabetes (DM group) while the control group included fetuses of euglycaemic healthy pregnant women. They were examined twice at 23–24 weeks' gestation (visit 1) and followed up at 27–28 weeks' gestation (visit 2). The Modified Myocardial Performance Index (Mod MPI) was obtained in all fetuses. Also, M-mode echocardiography was used to measure the interventricular septum thickness at diastole in a transverse four chamber view.

Results: There was a significant increase in Iso-volumetric contraction time (ICT) (45.4 ms ± 8.9), Iso-volumetric relaxation time (IRT) (54.7 ms ± 11.22), Interventricular septal thickness (IVST) (4.08 mm ± 0.8), aortic acceleration time (AAT) (54.16 ms ± 12.77) and MPI (0.64 ± 0.09) in the diabetic group compared to the normal control group ICT (38.5 ms ± 9.59), IRT (46.13 ms ± 10.29), IVST (3.17 mm ± 0.6), AAT (49.73 ms ± 10.68) and MPI (0.5 ± 0.1) (all P values were < 0.001).

When comparing parameters assessed at both visits among diabetic patients, there was a significant increase in IVST in the second visit (4.74 ± 0.78 mm) compared to the first visit (4.08 ± 0.8 mm) (P value < 0.05).

The incidence of hypertrophic cardiomyopathy (HCM) was significantly higher in diabetic patients than in the control group. This is was observed in both first and second visit (33.4% and 56.7%) (P value < 0.001).

Conclusions: Fetuses of diabetic pregnant females show a significant increase in MPI, decrease in E/A ratio and HCM. These alterations in cardiac functions and structure were found to be continuous throughout the period of time between the two visits.

Keywords: Diabetes Mellitus, Myocardial performance index, Interventricular septal thickness, Hypertrophic cardiomyopathy, Fetal echocardiography, Ultrasound and fetal scan

Background

It is estimated that by the year 2025, the global prevalence of diabetes will be about 6.3% [1]. At present, the prevalence of pregestational diabetes is 2.2% with an overall prevalence of hyperglycaemia in pregnancy of...
about 16.2% [2]. Despite advances in perinatal diagnosis and management, infants of diabetic mothers (IDM) continue to suffer from considerable morbidities and even mortality. One of these complications is asymmetric septal hypertrophy (ASH) [3, 4]. Diabetes Mellitus imposes an abnormal environment that affects fetal heart structure and function [5]. Insulin, endogenous catecholamines and some growth factors have all been implicated as possible causes for ASH [5]. Nevertheless there are conflicting reports about Diabetes and congenital heart disease where it has been stated that severe hypertrophic cardiomyopathy has been recorded in spite of good glycemic control of mothers [6, 7]. However, tight control of diabetes before pregnancy improves fetal outcomes [8].

It was initially believed that interventricular septal hypertrophy occurs late in pregnancy in association with abnormal diastolic function [9]. However, exposure to hyperglycemia is now thought to be the cause of Interventricular septal thickness (IVST), while good diabetic control seems to decrease this effect [10, 11]. It was reported that even transient exposure of rat fetuses to hyperglycemia was enough to induce inter ventricular septal hypertrophy [12]. Furthermore, IVST has been reported, also, as early as 13 weeks’ gestation in fetuses of diabetic controls [13]. Myocardial performance index (MPI) provides accurate estimation of both diastolic and systolic cardiac functions [14]. Antenatal MPI assessment has been demonstrated to successfully identify fetal ventricular dysfunction [15, 16]. The normal reference range for MPI has been reported to be 0.408 ± 0.08 SD and this does not seem to be affected by maternal age, body mass index (BMI) or parity [17].

Myocardial relaxation is affected by myocardial calcium uptake and this is thought to be affected by diabetes [18]. Indeed, Isovolumetric relaxation time (IRT) was noted to be significantly prolonged in IDM [19–21]. This was also reported as early as the first trimester in fetuses whose mothers have pregestational hyperglycaemia [22].

In contrast, the mitral E wave/A wave peak velocity (E/A) ratio, another indicator of diastolic ventricular function, has been shown to be significantly reduced in IDM [23].

There is a wide variation in the clinical presentation and natural history of myocardial hypertrophy and / or dysfunction in IDMs. Moreover, there is paucity of information relating to the impact of diabetes on fetal cardiac structure and function. [10, 24]. Therefore, the main aim of this study was to assess the impact of diabetes on IRT, MPI and E/A ratio as surrogate measures for myocardial function. Additionally, we wanted to assess the association of maternal diabetes with fetal cardiac structure, namely, IVST and hypertrophic cardiomyopathy (HCM).

Methods
The study was a prospective case control study conducted at the Maternal Fetal Medicine unit, Kasr Al-Ainy University Hospital, Cairo, Egypt, between May 2017 and May 2019. The study was approved by the department of Obstetrics and Gynecology ethical and scientific committee, Cairo University, under the No. I-251016. Women were only recruited into the study after they had signed an informed written consent.

Cases included fetuses of mothers known to have pre-gestational type 2 Diabetes (DM group) while the controls were fetuses of euglycaemic healthy pregnant women. The NICE guideline diagnostic criteria of overt pre-gestational Diabetes were used for this study [25]. Candidates were recruited from patients coming for routine second trimester anomaly scan at 23–24 weeks’ gestation (visit 1) and they were followed up at 27–28 weeks’ gestation (visit 2). Pre-gestational or pregnancy induced medical disorders (other than Diabetes), congenital fetal malformations, hydrops fetalis and intrauterine growth restriction were considered criteria for exclusion from the study.

Ultrasound examinations were performed by two independent operators; a fetal medicine specialist (AO), followed by an experienced fetal medicine consultant (RK), who was initially blind to AO’s measurements. In case of any discrepancies, a third assessment was performed by AO under RK’s supervision.

The Modified MPI (Mod MPI) was obtained in all fetuses using the technique described by H. Andrade et al. (Fig. 1) [14]. All measurements were done in the absence of fetal movements or respiratory movements. The velocity of the Doppler sweep on the ultrasound screen was the highest velocity available (15 cm/s) for clear identification of the components of the Doppler tracing. The E/A waveform was always displayed as positive flow, the angle of insonation was kept <30° and the mechanical and thermal indices did not exceed one. A cross-sectional image of the fetal thorax in the four-chamber view and an apical projection (anterior or posterior) of the heart were obtained (Fig. 1). The Doppler sample volume was placed on the lateral wall of the ascending aorta, below the aortic valve (AV) and just above the mitral valve (MV). The Doppler trace which showed a clear echo corresponding to the opening and closure of the two valves at the beginning and at the end of the E/A (mitral valve) and AV waveforms. The time periods were then estimated as follows: the Isovolumetric contraction time (ICT) was estimated from the closure of the MV to the opening of the AV, the ejection time (ET) from the opening to the closure of the AV, and the ICT...
from the closure of the AV to the opening of the MV. The final result for the Mod-MPI was calculated as: (ICT + IRT)/ET [14].

The peak velocity (in cm/s) of E wave (early filling) and A wave (atrial contraction) were done by measuring the M shaped wave representing the flow across the mitral valve. The wave with reversed flow after the E/A wave representing the aortic ejection through the aortic valve and its peak aortic velocity (PAV) were measured in cm/s. Aortic acceleration time (AAT) is the period between the opening of the AV and the peak velocity of flow through the valve (Fig. 2).

All septal measurements were taken during cardiac diastole. The septal thickness was taken as the distance between the outer edges of each margin. M-mode echocardiography was used to measure the interventricular septum at diastole in a transverse four chamber view. The M-mode trace line was placed perpendicular to the interventricular septum immediately below the atrioventricular valves (Fig. 3). Myocardial hypertrophy is defined as interventricular septum thickness at end-diastole greater than two standard deviations above the norm for gestational age [13].

Statistical analysis
Sample size calculation was done using the comparison of fetal IVST between mothers with pre-gestational type 2 Diabetes (DM group) and normal pregnant mothers being the primary outcome of the study. As reported in previous publication [4], the mean ± SD of IVST in DM group was 2.44 ± 0.62 mm and 1.9 ± 0.2 in normal group. Accordingly, the minimal proper sample size was 41 participant in each arm to be able to reject the null hypothesis with 80% power at α = 0.05 level using one way analysis of variance test.

Data were analyzed using IBM SPSS Statistics version 23 (IBM Corp., Armonk, NY). Continuous numerical variables were presented as mean and SD. Differences between the two groups were compared using unpaired t-test, comparison between the first and second visit were done using paired sample t-test. Categorical variables were presented as numbers and percentages and differences were compared using Fisher’s exact test. A P-value < 0.05 was considered statistically significant.

Results
A total of 120 pregnant women were recruited for the study (60 cases and 60 controls). Extra eight and seven women were lost to follow-up in the DM and control groups respectively, so they were not counted. There were no statistically significant differences between the two studied groups regarding the mean age, gravidity, parity and fetal gestational age at first and second visit (p value > 0.05), as shown in Table 1.

At visit 1, there was a significant increase in Iso-volumetric contraction time (ICT), Iso-volumetric contraction time (ICT),

\[ \text{(ICT + IRT)/ET} \]

...
relaxation time (IRT), Interventricular septal thickness (IVST), aortic acceleration time (AAT) and MPI in the Diabetic group compared to the control group (all p values were < 0.001) (Table 2). There was also a significant decrease in mitral E, mitral E/A ratio, peak aortic velocity (PAV), ventricular ejection time (VET),
ventricular filling time (VFT) in the Diabetic group compared to the normal control group ($p$ value < 0.05).

At visit 2, there was a significant increase in mitral A wave, ICT, IRT, IVST and MPI in the Diabetic group compared to the control group ($p$ value < 0.05). There was also a significant decrease in mitral E/A ratio, VET in the Diabetic group compared to the control group ($p$ value < 0.05) (Table 3).

When comparing parameters assessed at both visits among cases, there was a significant increase in IVST in the second visit compared to the first visit in the Diabetic group ($p$ value < 0.05), while there were no significant differences identified in mitral E/A ratio nor in MPI (Table 4).

Finally, the incidence of hypertrophic cardiomyopathy (HCM) was significantly higher in the Diabetic group than in the control group. This was found in both, the first and second visits ($p$ value < 0.001). (Table 5).

**Discussion**

**Summary of results**

Our results show significantly higher values of mitral ICT, IRT, IVST, MPI and IVST and significantly lower values for the mitral E/A ratio, VET in fetuses of diabetic mothers compared to those of non-diabetic mothers. This suggests that pre-gestational diabetes leads to impairment of the fetal cardiac functions and hypertrophic cardiomyopathy. Its pathophysiology is that hyperglycemia increases cord blood insulin like growth factor 1 (IGF-1). Obesity, hypertriglyceridemia, oxidative stress and cord blood elevated levels of IGF-1 are strongly associated with abnormal cardiac function of infants of diabetic mothers [26].

These changes persisted at the planned 3-week follow-up time interval and there was even a significant progression for some of the parameters over time.

### Table 1  The patient’s demographic characteristics in all studied groups

| Variable     | Normal control ($n = 60$) | DM ($n = 60$) | P-value |
|--------------|---------------------------|--------------|---------|
| Age (years)  | Mean(28.13) SD(6.73)      | Mean(30.06) SD(6.14) | 0.1     |
| Gravidity    | 3 (1—4)                   | 4 (2—5)      | 0.233   |
| Parity       | 2 (0—3)                   | 2 (1—3)      | 0.420   |
| Previous abortions | 0 (0—1)         | 0 (0—1)      | 0.312   |
| Previous CS  | 0 (0—1)                   | 1 (0—2)      | 0.051   |
| Previous NVD | 0 (0—2)                   | 1 (0—1)      | 0.169   |
| GA at visit 1 (weeks) | Mean(24.1) SD(0.8) | Mean(24.35) SD(0.93) | 0.4     |
| GA at visit 2 (weeks) | Mean(27.6) SD(0.7) | Mean(28.05) SD(0.74) | 0.052   |

DM Diabetes Mellitus, CS Cesarian Section, NVD Normal Vaginal Delivery, GA Gestational Age

### Table 2  Echocardiographic measures at visit 1 (23–24 weeks) in the studied groups

| Variable     | Normal control ($n = 60$) | DM ($n = 60$) | P-value |
|--------------|---------------------------|--------------|---------|
| Mitral E (cm/s) | 30.7 8.24 | 27.2 6.15 | 0.009   |
| Mitral A (cm/s) | 46 12.22 | 49.41 11.23 | 0.11    |
| Mitral E/A    | 0.67 0.11 | 0.55 0.05 | < 0.001 |
| PAV (cm/s)    | 69.38 25.46 | 60.06 15.75 | 0.017   |
| AAT (ms)      | 49.73 10.68 | 54.16 12.77 | 0.04    |
| VFT (ms)      | 172.06 28.38 | 161 31 | 0.04    |
| ICT (ms)      | 38.5 9.59 | 45.4 8.9 | < 0.001 |
| VET (ms)      | 170.3 14.8 | 151 21.5 | < 0.001 |
| IRT (ms)      | 46.13 10.29 | 54.7 11.22 | < 0.001 |
| MPI           | 0.5 0.1 | 0.64 0.09 | < 0.001 |
| IVST (mm)     | 3.17 0.6 | 4.08 0.8 | < 0.001 |

PAV peak aortic velocity, AAT aortic acceleration time, VFT ventricular filling time, ICT Iso-volumetric contraction time, VET ventricular ejection time, IRT Iso-volumetric relaxation time, MPI Myocardial Performance Index, IVST Interventricular septal thickness

### Table 3  Echocardiographic measures at visit 2 (27–28 weeks) in the study groups

| Variable     | Normal control ($n = 60$) | DM ($n = 60$) | P-value |
|--------------|---------------------------|--------------|---------|
| Mitral E (cm/s) | 30.3 5.74 | 29.27 5.5 | 0.3     |
| Mitral A (cm/s) | 45.9 8.6 | 51.46 8.76 | < 0.001 |
| Mitral E/A    | 0.66 0.08 | 0.56 0.039 | < 0.001 |
| PAV (cm/s)    | 67.5 14.37 | 64.21 14.35 | 0.2     |
| AAT (ms)      | 56.06 11.08 | 55.28 9.32 | 0.6     |
| VFT (ms)      | 168.78 28.5 | 168.8 26.03 | 0.9     |
| ICT (ms)      | 35.7 7.4 | 44.85 9.66 | < 0.001 |
| VET (ms)      | 169.2 11.4 | 151.33 10.79 | < 0.001 |
| IRT (ms)      | 41.86 7.74 | 57.36 7.33 | < 0.001 |
| MPI           | 0.46 0.09 | 0.67 0.09 | < 0.001 |
| IVST (mm)     | 3.57 0.52 | 4.74 0.78 | < 0.001 |

PAV peak aortic velocity, AAT aortic acceleration time, VFT ventricular filling time, ICT Iso-volumetric contraction time, VET ventricular ejection time, IRT Iso-volumetric relaxation time, MPI Myocardial Performance Index, IVST Interventricular septal thickness
Interpretation in light of what is known

We assessed the effect of maternal Diabetes on fetal left ventricular MPI and observed that fetuses of diabetic mothers had consistently significantly high left ventricular MPI values. Similarly, IRT and ICT were significantly increased in the group of fetuses of diabetic mothers compared to the control group. In contrast, VET was significantly lower in fetuses of diabetic mothers compared to non-diabetic mothers. MPI as an indicator of global cardiac function [14], was found to be significantly increased in fetuses of diabetic mothers. This finding was in agreement with previously published studies [13, 19–21]. In the previously cited studies the researchers assessed each fetus only once, in the second trimester, whereas in our study we did a second assessment to explore whether this deterioration would persist.

Our results showed significant decrease in mitral E/A ratio in the diabetic group compared to the control group in both first and second visits. The decreased E/A ratio of mitral valve indicated diastolic malfunction of the heart. These results were in concordance with previous studies [13, 19–21]. Other studies have excluded mitral E/A ratio changes in patients with controlled gestational diabetes [23, 27]. Fouda et al. [23] compared gestational diabetes and type II diabetes effect on fetuses and concluded that maternal gestational diabetes does not affect tricuspid and mitral E/A ratios. However, they included smaller study groups (47 diabetics and 44 gestational diabetes) and performed a single assessment session. Wong et al. [27] had examined fetal mitral and tricuspid E/A ratio in three settings (two were at early and late second trimester and the third was at third trimester) in women with gestational diabetes but they choose women with mild gestational impaired glucose tolerance (GIGT) and had a smaller study group (37 women).

In our study, IVST was found to be significantly increased in fetuses of diabetic mothers compared to fetuses of non-diabetic mothers in both visits. Moreover, by comparing the values of IVST between the two visits in the diabetic group, we also found a significant increase in IVST values. This agrees with previous studies [4, 13, 28] which indicated that IVST had a progressive course throughout pregnancy and did not show only a simple increase, but rather a significant increase when comparing the two examinations.

Limitations to our study were the relatively low number of the study group, the lack of clinical information about glycaemic control of the mothers and the deficiency of postnatal data regarding the neonatal heart examination for those fetuses after delivery. Also, non-consecutive sampling might have introduced selection bias. However, independent reviewers, comprehensive parameters and prospective data collection could be regarded as strong points of this study.

Conclusion

In conclusion, fetuses with diabetic mothers have a significant increase in MPI and a significant decrease in the E/A ratio and HCM. These alterations in cardiac functions and structure were found to be continuous throughout the period of time between the two visits. This raises

| Variable | Mean | SD | Mean | SD | P value |
|----------|------|----|------|----|---------|
| Mitral E (cm/s) | 27.2 | 6.15 | 29.27 | 5.5 | 0.006 |
| Mitral A (cm/s) | 49.41 | 11.23 | 51.46 | 8.76 | 0.16 |
| Mitral E/A | 0.55 | 0.05 | 0.56 | 0.039 | 0.02 |
| PAV (cm/s) | 60.06 | 15.75 | 64.21 | 14.35 | 0.06 |
| AAT (ms) | 54.16 | 12.77 | 55.28 | 9.32 | 0.44 |
| VFT (ms) | 161.31 | 168.8 | 26.03 | 0.1 |
| ICT (ms) | 45.4 | 8.9 | 44.85 | 9.66 | 0.62 |
| VET (ms) | 151 | 21.5 | 151.33 | 10.79 | 0.9 |
| IRT (ms) | 54.7 | 11.22 | 57.36 | 7.33 | 0.06 |
| MPI | 0.64 | 0.09 | 0.67 | 0.09 | 0.04 |
| IVST (mm) | 4.08 | 0.8 | 4.74 | 0.78 | <0.001 |

Table 5 Prevalence of hypertrophic cardiomyopathy HCM at visit 1 and visit 2 between study groups

| Variable | Normal control (n = 60) | DM (n = 60) | P-value |
|----------|------------------------|-------------|---------|
| HCM at visit 1 | No HCM 58 | 96.7% | 40 | 66.6% | <0.001 |
| HCM | 2 | 3.3% | 20 | 33.4% |
| HCM at visit 2 | No HCM 60 | 100.0% | 26 | 43.3% | <0.001 |
| HCM | 0 | 0.0% | 34 | 56.7% |

* Fisher’s exact test
the importance of strict glycemic control before pregnancy and throughout pregnancy in diabetic patients. Also, early diagnosis and management of gestational diabetes helps in reduction of the adverse effects on the fetal heart. We recommend further studies for the effect of good glycemic control on fetal heart in diabetic mothers to be run on larger study groups with post-natal echocardiographic assessment.

**Abbreviations**

AAT: Aortic Acceleration Time; AV: Aortic Valve; ASH: Asymmetric Septal Hypertrophy; BMI: Body Mass Index; CS: Cesarian Section; DM: Diabetes Mellitus; ET: Ejection Time; GA: Gestational Age; HCM: Hypertrophic Cardiomyopathy; IDM: Infants of Diabetic Mothers; IGF‑1: Insulin like Growth Factor 1; IVST: Isovolumetric Septal Thickness; ICT: Isovolumetric Contraction Time; IDM: Infants of Diabetic Mothers; IGF‑1: Insulin like Growth Factor 1; IRT: Isovolumetric Relaxation Time; MV: Mitral Valve; MPI: Myocardial Performance Index; NVD: Normal Vaginal Delivery; PAV: Peak Aortic Velocity; VET: Ventricular Ejection Time; VFT: Ventricular Filling Time.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s12884-022-04969-5.

**Additional file 1.**

**Acknowledgements**
The authors appreciate the help of all pregnant women enrolled in this study and the Maternal Fetal medicine unit, Kasr El Aini Hospital, Cairo University.

**Authors’ contributions**

AO and RK performed the ultrasound scanning, all authors shared in the conception of the idea and the study design, MS was responsible of data gathering and statistical analysis. AO and RK have done manuscript writing and reviewing. All authors shared in revising the manuscript. The author(s) read and approved the final manuscript.

**Funding**

Open access funding provided by The Science, Technology & Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB).

**Availability of data and materials**

The datasets used and/or analyzed during the current study belongs to the Maternal Fetal Medicine Unit, Cairo University and due to its internal regulations these data are only available from the corresponding author on reasonable request. The Raw data generated and analyzing during the study are present in manuscript and its supplementary information file.

**Declarations**

**Ethics approval and consent to participate**

Authors confirmed that all methods were carried out in accordance with relevant guidelines and regulations. The study was approved by the department of obstetrics and gynecology medical ethical committee, Cairo University, under the No. I-251016. Women were only recruited into the study if they provided an informed written consent.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1. Department of Obstetrics and Gynecology, Faculty of Medicine, Kasr El Aini Hospital, Cairo University, Cairo, Egypt.
2. High Risk Pregnancy Unit, Department of Obstetrics and Gynecology, Faculty of Medicine, Kasr El Aini Hospital, Cairo University, Cairo, Egypt.
3. Maternal Fetal Medicine Unit, Department of Obstetrics and Gynecology, Kasr El Aini Hospital, Cairo University, Cairo, Egypt.
4. Department of Obstetrics and Gynecology, Embaba General Hospital, Egyptian Ministry of Health and Population, Giza, Egypt.
5. Department of Reproductive Health and Family Planning, Medical Research Institute, National Research Centre, Cairo, Egypt.

**Received: 7 February 2022 Accepted: 4 August 2022**

**References**

1. Atlas D: International diabetes federation. IDF Diabetes Atlas, 7th edn Brussels, Belgium: International Diabetes Federation 2015.
2. Yuen L, Saeedi P, Riaz M, Karuranga S, Divakar H, Levitt N, Yang X, Simmonds D. Projections of the prevalence of hyperglycemia in pregnancy in 2019 and beyond: Results from the International Diabetes Federation Diabetes Atlas. Diabetes Res Clin Pract. 2019;157: 107841.
3. Peterson B, Hansson U. Neonatal morbidity in gestational diabetes mellitus. Diabetes Care. 1998;21:879.
4. Vela-Huerta MM, Vargas-Origel A, Olvera-López A. Asymmetrical septal hypertrophy in newborn infants of diabetic mothers. Am J Perinatol. 2000;17(02):089–94.
5. Breitwieser JA, Meyer RA, Sperling MA, Tsang RC, Kaplan S. Cardiac septal hypertrophy in hyperinsulinemic infants. J Pediatr. 1988;96(3):359–9.
6. Weber HS, Copel JA, Reece EA, Green J, Kleinman CS. Cardiac growth in fetuses of diabetic mothers with good metabolic control. J Pediatr. 1991;118(1):103–7.
7. Vincent M, Benbrik N, Romefort B, Colombel A, Bézieau S, Isidor B. Three patients presenting with severe macrosomia and congenital hypertrophic cardiomyopathy: a case series. J Med Case Reports. 2017;11(1):78.
8. To WW: Applications of doppler studies for fetal surveillance in diabetic pregnancies. Gestational Diabetes 2011;26:4–276.
9. MIYAKE T: Doppler echocardiographic studies of diastolic cardiac function in the human fetal heart. The Kurume medical journal 2001, 48(1):59–64.
10. Zhielinsky P, Piccoli AL Jr. Myocardial hypertrophy and dysfunction in maternal diabetes. Early Human Dev. 2012;88(5):273–8.
11. Mert MK, Sarar M, Özbársal N, Yaman A, Özgün EK, Asker HS, Kekünmez EK, Toker T, Troponin T and NT ProBNP levels in gestational, type 1 and type 2 diabetic mothers and macroscopic infants. Pediatr Cardiol. 2016;37(1):76–83.
12. Gordon EE, Reinking BE, Hu S, Yao J, Kua KL, Younes AK, Wang C, Segar JL, Norris AW: Maternal hyperglycemia directly and rapidly induces cardiac septal overgrowth in fetal rats. Journal of diabetes research 2015, 2015.
13. Russell NE, Foley M, Kinsley BT, Firth RG, Coffey M, McAuliffe FM: Effect of pregestational diabetes mellitus on fetal cardiac function and structure. American journal of obstetrics and gynecology 2008, 199(3):312. e311–312. e317.
14. Hernandez-Andrade E, Figueroa-Diesel H, Kottman C, Illanes S, Arraztoa J, Acosta-Rojas R, Gratacos E. Gestational-age-adjusted reference values for the modified myocardial performance index for evaluation of fetal left cardiac function. Ultrasound in Obstetrics and Gynecology: The Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology. 2007;29(3):321–5.
15. Ichizuka K, Hasegawa J, Shirato N, Jimbo M, Otsuki K, Sekizawa A, Farina A, Okai T. The Tei index for evaluation of fetal myocardial performance in sick fetuses. Early Human Dev. 2005;81(3):273–9.
16. Chavengsartkul S, Pussameecharoen K, Wanitpongpan P. Fetal cardiac function measured by myocaridial performance index of small-for-gestational age fetuses. Journal of Obstetrics and Gynaecology Research. 2015;41(2):222–8.
17. Ali S, Okasha A, Elsirgany S, Elanwary S, Abdul-Rasheed M, Khalil A, Elsheikhah A. Normal reference ranges for fetal cardiac function: Assessed by modified Doppler myocardial performance index (Mod MPI) in the Egyptian population. Eur J Obstet Gynecol Reprod Biol. 2020;251:66–72.
18. Reis ZSN, Osanan GC. Congenital cardiopathies screening associated with diabetes mellitus using maternal fructosamine plasma concentration. Gestational diabetes 2011:255.

19. Atiq M, Ikram A, Hussain BM, Saleem B. Assessment of cardiac function in fetuses of gestational diabetic mothers during the second trimester. Pediatr Cardiol. 2017;38(5):941–5.

20. Balli S, Pac FA, Ece I, Offaz MB, Kibar AE, Kandemir O. Assessment of cardiac functions in fetuses of gestational diabetic mothers. Pediatr Cardiol. 2014;35(1):30–7.

21. Sanhalı CY, Daglar HK, Kara O, Uyygur D, Yucel A. Assessment of fetal myocardial performance index in women with pregestational and gestational diabetes mellitus. Journal of Obstetrics and Gynaecology Research. 2017;43(1):65–72.

22. Turan S, Turan O, Miller J, Harman C, Reece E, Baschat A. Decreased fetal cardiac performance in the first trimester correlates with hyperglycemia in pregestational maternal diabetes. Ultrasound Obstet Gynecol. 2011;38(3):525–31.

23. Fouda UM, Abou ElKassem MM, Hefny SM, Fouda RM, Hashem AT. Role of fetal echocardiography in the evaluation of structure and function of fetal heart in diabetic pregnancies. J Matern Fetal Neonatal Med. 2013;26(6):571–5.

24. Kozák-Báránay A, Jokinen E, Kero P, Tuominen J, Rönnemaa T, Välimäki I. Impaired left ventricular diastolic function in newborn infants of mothers with pregestational or gestational diabetes with good glycemic control. Early Human Dev. 2004;77(1–2):13–22.

25. Webber J, Charlton M, Johns N. Diabetes in pregnancy: management of diabetes and its complications from preconception to the postnatal period (NG3). British Journal of Diabetes. 2015;15(3):107–11.

26. Pauliks LB. The effect of pregestational diabetes on fetal heart function. Expert Rev Cardiovasc Ther. 2015;13(1):67–74.

27. Wong M, Wong W, Cheung Y. Fetal myocardial performance in pregnancies complicated by gestational impaired glucose tolerance. Ultrasound in Obstetrics and Gynecology: The Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology. 2007;29(4):395–400.

28. Garg S, Sharma P, Sharma D, Behera V, Durairaj M, Dhall A. Use of fetal echocardiography for characterization of fetal cardiac structure in women with normal pregnancies and gestational diabetes mellitus. J Ultrasound Med. 2014;33(8):1365–9.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.